These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31784440)

  • 1. Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study.
    Guan X; Wushouer H; Yang M; Han S; Shi L; Ross-Degnan D; Wagner AK
    BMJ Open; 2019 Nov; 9(11):e031658. PubMed ID: 31784440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study.
    Wushouer H; Luo Z; Guan X; Shi L
    Int J Health Policy Manag; 2022 Feb; 11(2):218-223. PubMed ID: 32702801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
    Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
    BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does price deregulation increase drug price in China? An interrupted time series analysis.
    Xiong Y; Xu J; Gao Y
    Int J Health Plann Manage; 2021 Sep; 36(5):1653-1665. PubMed ID: 34028086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
    Rong X; Yin J; Duan S; Sun Q; Babar ZU
    BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study.
    Hsu JC; Lu CY; Wagner AK; Chan KA; Lai MS; Ross-Degnan D
    Health Policy; 2014 Jun; 116(2-3):196-205. PubMed ID: 24314624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.
    Guan X; Tian Y; Ross-Degnan D; Man C; Shi L
    BMJ Open; 2018 Jul; 8(7):e022328. PubMed ID: 30012792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis.
    Wang J; Li P; Wen J
    BMC Health Serv Res; 2020 Jun; 20(1):519. PubMed ID: 32513170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis.
    Sun Y; Zhu Z; Zhang J; Han P; Qi Y; Wang X; Yang L
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
    Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
    BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
    Wang N; Yang Y; Xu L; Mao Z; Cui D
    BMC Public Health; 2021 Oct; 21(1):1883. PubMed ID: 34663282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulation and pricing of medical services: a policy experiment based in China.
    Zang W; Zhou M; Zhao S
    BMC Health Serv Res; 2021 May; 21(1):501. PubMed ID: 34034722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals.
    Meng Q; Cheng G; Silver L; Sun X; Rehnberg C; Tomson G
    Health Policy Plan; 2005 May; 20(3):185-96. PubMed ID: 15840634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series.
    Long H; Yang Y; Geng X; Mao Z; Mao Z
    Front Pharmacol; 2022; 13():944540. PubMed ID: 35910351
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of China's healthcare price reforms on traditional Chinese medicine public hospitals in Beijing: an interrupted time-series study.
    Zhu D; Shi X; Nicholas S; Bai Q; He P
    BMJ Open; 2019 Aug; 9(8):e029646. PubMed ID: 31401602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of price deregulation policy on the affordability of essential medicines for women's health: a panel data analysis.
    Liu J; Wang L; Liu C; Zhang X
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):625-631. PubMed ID: 28503962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of policy on availability and price of low-price medicines in public healthcare institutions: A retrospective survey in Nanjing, China.
    Zhu Y; Ren Y; Wang H; Fang W; Xu X; Wang Y; Dai H; Li X
    Int J Health Plann Manage; 2022 Mar; 37(2):1118-1130. PubMed ID: 34850454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
    Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
    Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of the implementation of low price medicine policy on medicine price in China: A retrospective study.
    Guan X; Yang M; Man C; Tian Y; Shi L
    Int J Health Plann Manage; 2018 Apr; ():. PubMed ID: 29709071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis.
    Yi H; Shi F; Wang Z; Kuai L; Xu D; Xie Y; Xing H
    BMJ Open; 2023 Oct; 13(10):e064811. PubMed ID: 37852769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.